



Toronto, Ontario, Canada
TSX-V Symbol: NXG

December 29, 2017

NEWS RELEASE

**NEXGENRX ANNOUNCES COMPLETION OF
\$1,750,000 EQUITY FINANCING**

For Immediate Release

December 29, 2017: Toronto, Ontario – NEXGENRX INC. ("NexgenRx" or the "Corporation") announces the completion of a private placement financing, pursuant to which it has issued an aggregate of 7,000,000 common shares of the Corporation (each, a "Common Share") at a price of \$0.25 per Common Share for aggregate gross proceeds of \$1,750,000. The proceeds of this offering will be used to fund future technology, product and software development, as well as to provide general working capital for 2018. Four-month hold periods apply to the securities issued under this offering (expiring April 30, 2018) in accordance with applicable securities laws. One insider (being the President and Chief Executive Officer) participated in the offering, acquiring 237,575 Common Shares. The foregoing subscription is considered to be a related party transaction and is therefore subject to the provisions of Multilateral Instrument 61-101 – "*Protection of Minority Security Holders in Special Transactions*", however exemptions are available from the minority shareholder approval and valuation requirements set forth in the foregoing Multilateral Instrument.

About NexgenRx

NexgenRx is Canada's only independent full service claims adjudicator with full front end administration capability. These combined capabilities allow NexgenRx to provide complete solutions to plan sponsors that need sophisticated health benefit technology applications, in a cost-effective manner. NexgenRx is committed to building partnerships with organizations looking to exceed the expectations of their clients and deliver superior administration and claims processing solutions at a competitive cost. More information on NexgenRx can be found at www.nexgenrx.com.

Caution Regarding Forward-Looking Statements – This news release contains certain forward looking statements, including statements regarding the business and anticipated financial performance of the Corporation. These statements are subject to a number of risks and uncertainties. Actual results may differ materially from results contemplated by the forward-looking statements. When relying on forward-looking statements to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and should not place undue reliance on such forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release.

FOR FURTHER INFORMATION PLEASE CONTACT:

Ronald C. Loucks
NexgenRx Inc.
President and CEO
416.695.3393 x801

Kelly Ehler CPA, CA
NexgenRx Inc.
Chief Financial Officer
416-695-3393x803